Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus

BACKGROUND: Given the modest responses to everolimus, a mTOR inhibitor, in multiple tumor types, there is a pressing need to identify predictive biomarkers for this drug. Using targeted ultra-deep sequencing, we aimed to explore genomic alterations that confer extreme sensitivity to everolimus. RESU...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Sun Min, Park, Hyung Soon, Kim, Sangwoo, Kim, Sora, Ali, Siraj M., Greenbowe, Joel R., Yang, In Seok, Kwon, Nak-Jung, Lee, Jae Lyun, Ryu, Min-Hee, Ahn, Jin-Hee, Lee, Jeeyun, Lee, Min Goo, Kim, Hyo Song, Kim, Hyunki, Kim, Hye Ryun, Moon, Yong Wha, Chung, Hyun Cheol, Kim, Joo-Hang, Kang, Yoon-Koo, Cho, Byoung Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891139/
https://www.ncbi.nlm.nih.gov/pubmed/26859683
http://dx.doi.org/10.18632/oncotarget.7234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891139/
https://www.ncbi.nlm.nih.gov/pubmed/26859683
http://dx.doi.org/10.18632/oncotarget.7234

Ejemplares similares